Iridex Corporation — Third Quarter 2026 Earnings Summary
Financial Performance:
- Total revenue for the three months ended October 3, 2026, was $10.2 million, a 19% decline from $12.5 million in the prior year period.
- Retina product revenue was $5.1 million, down from $6.7 million in the prior year period.
- Cyclo G6 product family revenue was $3.2 million, down from $3.5 million in the prior year period; approximately 11,900 probes were sold compared to 14,900 in the prior year, and 28 Glaucoma Laser Systems were sold compared to 30.
- Other revenue was $1.9 million, down from $2.2 million, driven by lower service revenue and the absence of royalty revenue.
- Gross margin increased to 42.4% from 32.1% in the prior year period and 34.2% in the second quarter of 2026; pro forma gross margin excluding a one-time $0.8 million write-off from the prior year was 38.7%.
- Operating expenses were $5.5 million, essentially flat compared to $5.4 million in the prior year period.
- Net loss was $1.4 million ($0.08 per share), compared to a net loss of $1.6 million ($0.09 per share) in the prior year period.
- Non-GAAP adjusted EBITDA loss was $0.6 million, compared to a loss of $0.1 million in the prior year period.
- Cash and cash equivalents were $3.7 million as of October 3, 2026, a decrease of $1.0 million from July 4, 2026.
- Accounts receivable were $4.8 million as of October 3, 2026, down from $9.5 million at the beginning of the year; inventories were $11.8 million, up from $7.9 million.
- Convertible note payable was $3.8 million as of October 3, 2026, up from $3.7 million at the beginning of the year.
Guidance and Future Outlook:
- Full-year 2026 revenue guidance was reduced to between $46 million and $48 million, down from the prior range of $51 million to $53 million, excluding Middle East revenue.
- Fiscal year 2026 adjusted operating expenses (excluding depreciation, amortization, and stock-based compensation) are expected to remain between $19 million and $19.5 million.
- Management expects cash utilization to decrease significantly in the fourth quarter due to stronger sales and the reversal of inventory stocking processes.
- The company anticipates entering 2027 with better margins, a lower cost base, and a business model better aligned toward cash flow generation.
- The transition of major products to third-party contract manufacturers is expected to be a significant driver of margin expansion through 2027.
Business Segments and Product Lines:
- The U.S. glaucoma business showed growth, partially offsetting declines in international retina sales and probe orders.
- International revenue declined as distributors worked through inventory purchased earlier in the year.
- Higher U.S. probe average selling prices and higher system revenue partially offset international declines in the Cyclo G6 segment.
- The company is deep into a strategic review of product lines and is reprioritizing resources toward the most profitable opportunities.
Market and Competitive Landscape:
- Revenue was impacted by weaker than anticipated customer demand in Europe and Asia.
- Ongoing regulatory challenges contributed to order delays late in the quarter.
- Distributors experienced delays as they worked through existing probe inventory.
Risks and Challenges:
- Weaker international demand and regulatory challenges pose risks to revenue generation.
- Inventory management during the manufacturing facility transition required investment, impacting cash utilization.
- The company faces headwinds from international market declines and distributor inventory adjustments.
Management Commentary and Tone:
- Patrick Mercer, President and CEO, stated that revenue came in below expectations due to international demand weakness and order delays.
- Management highlighted benefits from cost savings programs initiated under the new CEO, including the headquarters relocation expected to deliver approximately $600,000 in annualized savings.
- Management expressed confidence that the strategic review and reprioritization of resources will lead to improved financial performance in 2027.
Other Key Points:
- The company completed a headquarters relocation to San Jose, expected to deliver approximately $600,000 in annualized savings.
- A one-time write-off of approximately $0.8 million was recorded in the third quarter of 2025 related to cost of goods sold.
- The company excludes revenue from the Middle East in its full-year guidance.
- Non-GAAP adjustments included severance-related expenses, reconvention of shareholders' meeting expenses, legal settlement expenses, and inventory write-downs.
- Company
- IRIDEX CORP
- Sector
- Healthcare
- Industry
- Medical Devices